CheckMate-227

一行要約

1L 進行 NSCLC (EGFR/ALK 陰性) への Nivolumab + Ipilimumab vs 化療の phase III (複雑な multi-arm 試験)。Chemo-free dual IO 1L を確立、PD-L1 ≥1% で OS HR 0.79、<1% で 0.62。化療回避による long-term plateau 形成。

試験デザイン

• 対象: Stage IV NSCLC、EGFR/ALK 陰性、N=2877 (multi-arm)
• Part 1a (PD-L1 ≥1%): Nivo+Ipi vs Nivo monotherapy vs chemo
• Part 1b (PD-L1 <1%): Nivo+Ipi vs Nivo+chemo vs chemo
• 当初 TMB-high primary endpoint: 後に protocol 改訂で PD-L1 ≥1% OS が primary

主要結果

• OS PD-L1 ≥1% (Nivo+Ipi vs chemo): HR 0.79 (95% CI 0.67–0.94, p=0.007), median 17.1 vs 14.9 mo
• OS PD-L1 <1% (Nivo+Ipi vs chemo): HR 0.62, median 17.2 vs 12.2 mo
• 5-year update: 5-yr OS 24% (Nivo+Ipi) vs 14% (chemo) PD-L1 ≥1%; 19% vs 7% PD-L1 <1%
• AE: Grade 3-4 32.8% (dual IO) vs 36.0% (chemo) — IO は重症 irAE 増加

臨床的意義

• Chemo-free dual IO 1L 標準を確立 (IO+chemo と並ぶ選択肢)
• 化療回避による QoL 維持と long-term plateau formation
• Subgroup 限定: PD-L1 ≥1% (特に高発現) と TMB-high 議論的
• 派生試験: CheckMate-9LA (dual IO + 限定 chemo)、CheckMate-816 (neoadjuvant dual IO+chemo)

Open Questions

• Dual IO vs IO+chemo の使い分け: PD-L1 ≥50% / <50% での差別化、organ-specific (liver / brain met)
• TMB-high biomarker の臨床実装: assay 標準化、cutoff、PD-L1 との combined use
• Long-term plateau の特徴: 5-yr 後 cure fraction、再発時の re-challenge response
• irAE 高頻度の管理: 低用量 Ipilimumab regimen (1mg/kg q6w) の試験

重要論文 Top 10

1. NEJM-2019-Hellmann-Nivolumab plus ipilimumab in advanced non-small-cell lung cancer — CheckMate-227 part 1 primary
2. JTO-2024-Brahmer-Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment of metastatic non-small-cell lung cancer in CheckMate 227 — 5-yr update — long-term plateau
3. ★★★★ Hellmann et al. NEnglJMed 2018 — Original TMB-high analysis
4. ★★★★ Hellmann et al. CancerCell 2018 — Genomic biomarker predictors
5. JTO-2024-Reck-First-line nivolumab plus ipilimumab plus chemotherapy in patients with advanced non-small cell lung cancer CheckMate 9LA 4-year follow-up — CheckMate-9LA — dual IO+limited chemo evolution

関連エンティティ

• 薬剤クラス: PD-1-inhibitor (Nivolumab), CTLA-4-inhibitor (Ipilimumab)
• 関連試験: CheckMate-9LA / CheckMate-816 / CheckMate-743 / KEYNOTE-189 / KEYNOTE-024
• biomarker: PD-L1, TMB, TP53
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 52 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Bongiovanni et al. FrontImmunol 2021 — Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and

Basic-Immunotherapy

• Montesion et al. CancerDiscov 2021 — Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden
• Meric-Bernstam et al. Lancet 2021 — Enhancing anti-tumour efficacy with immunotherapy combinations

Basic-Liquid-biopsy

• Si et al. ClinCancerRes 2021 — A blood based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment Results from t…

Clinical-Epidemiology

• Global Burden of Disease 2019 Cancer Collaboration et al. JAMAOncol 2022 — Cancer incidence, moratlity, years of life lost, years live with disability, and disability-adjusted life years for 2…
• Thai et al. Lancet 2021 — Lung Cancer

Clinical-NEC

• Lindsay et al. BrJCancer 2021 — Large cell neuroendocrine lung carcinoma consensus statement from the british thoracic oncology group and the

Clinical-NSCLC-Driver negative

• Rodriguez-Abreu et al. AnnOncol 2021 — Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous
• Sha et al. CancerDiscov 2020 — Tumor mutational burden as a predictive biomarker in solid tumors
• Sakai et al. CancerSci 2021 — Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
• Doroshow et al. ClinCancerRes 2019 — Immunotherapy in non-small cell lung cancer facts and hopes
• Borghaei et al. ClinCancerRes 2026 — Early detriment analysis of first-line nivolumab plus ipilimumab-based therapy in patients with metastatic non-small
• Peruzzo et al. ClinLungCancer 2025 — Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1-negative squamous cell lung carcinoma A systematic review
• Reck et al. ESMOOpen 2021 — First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in
• Gridelli et al. ESMOOpen 2022 — First-line immunotherapy in advanced NSCLC patients with ECOG PS 2 results of an international expert Panel meeting b…
• Carbone et al. ESMOOpen 2025 — Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy
• Rizvi et al. JAMAOncol 2020 — Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell
• Gettinger et al. JAMAOncol 2021 — Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer the
• DiFederico et al. JAMAOncol 2026 — PD-(l)1 inhibitor monotherapy vs chemoimmunotherapy
• Boyer et al. JClinOncol 2021 — Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score
• Reuss et al. JImmunotherCancer 2020 — Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
• Ulas et al. JImmunotherCancer 2026 — Rescue by radiotherapy and anti-CTLA4PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC the
• Lantuejoul et al. JThoracOncol 2020 — Interobserver reliability of programmed cell death ligand-1 scoring using the VENTANA PD-L1 (SP263) assay in NSCLC
• Paz-Ares et al. JThoracOncol 2020 — A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC
• Paz-Ares et al. LancetOncol 2021 — First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung
• DiFederico et al. LancetOncol 2025 — Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in

Clinical-NSCLC-Driver-Other

• Caswell et al. TrendsCancer 2026 — Lung cancer in never smokers from early detection to prevention

Clinical-Others

• Li et al. FrontImmunol 2026 — Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer a

Clinical-irAE

• Shankar et al. JAMAOncol 2020 — Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell